Elevated biomarkers lead to diminished quality of life in heart attack patients post-discharge

Nov 16, 2009

Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study.

The study examined a subset of patients in a 4,500-patient registry from 24 24 U.S. hospitals and found:

  • 9 percent had elevated levels of the biomarker (TnT) after six months.
  • 33 percent had elevated level of the biomarker N-terminal pro-B-type Natriuretic Peptide (NTBNP) after six months.

Both TnT and NTBNP are associated with shortness of breath; NTBNP is associated with . A biomarker is a protein measured in the blood whose concentration can indicate the presence or severity of disease.

The study is being presented at the American Heart Association's annual scientific conference Nov. 14-18 in Orlando.

"These elevated biomarkers are definitely associated with a reduced quality of life for patients and may signal even worse outcomes," says David Lanfear, M.D., a heart failure physician at Henry Ford and lead author of the study.

"This data raises two important issues. The first is whether the biomarkers are a sign of ongoing problems or a reflection of the past heart attack itself. The second is whether closer monitoring of patients post heart attack can help target our treatment to those who need it most."

For the study, researchers assessed the levels in patients one month and six months following their discharge from the hospital. At one and six months, 14 percent and 9 percent of patients had elevated levels of TnT; at one and six months, 55 percent and 33 percent of patients had elevated levels of NTBNP.

Source: Henry Ford Health System (news : web)

Explore further: Team identifies new mechanism for misfolded proteins in heart disease

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

A hybrid vehicle that delivers DNA

8 hours ago

A new hybrid vehicle is under development. Its performance isn't measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.